Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Martine Escoffre, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Herve Avet-Loiseau, Alexandra Jobert, Lucie Planche, Jill Corre, Philippe Moreau

Blood (2024) 143 (20): 2029–2036.

https://doi.org/10.1182/blood.2023023597

Published: 2024

Includes: Supplemental data

Journal Articles

Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Blood (2023) 142 (Supplement 1): 4641.

https://doi.org/10.1182/blood-2023-181595

Published: 2023

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Blood (2023) 142 (Supplement 1): 6724.

https://doi.org/10.1182/blood-2023-186599

Published: 2023

Journal Articles

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Olivier Decaux, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Jill Corre, Alexandra Jobert, Lucie Planche, Herve Avet-Loiseau, Philippe Moreau

Blood (2023) 142 (Supplement 1): 207.

https://doi.org/10.1182/blood-2023-174044

Published: 2023

Journal Articles

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Blood (2023) 142 (Supplement 1): 6741.

https://doi.org/10.1182/blood-2023-185699

Published: 2023

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Blood (2022) 140 (Supplement 1): 10150–10153.

https://doi.org/10.1182/blood-2022-163335

Published: 2022

Journal Articles

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Blood (2022) 140 (Supplement 1): 4423–4425.

https://doi.org/10.1182/blood-2022-168742

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Blood (2022) 140 (Supplement 1): 7297–7300.

https://doi.org/10.1182/blood-2022-163494

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Blood (2022) 140 (Supplement 1): 10133–10136.

https://doi.org/10.1182/blood-2022-163555

Published: 2022

Journal Articles

Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

Blood (2021) 138 (Supplement 1): 4095.

https://doi.org/10.1182/blood-2021-150369

Published: 2021

Journal Articles

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

Blood (2021) 138 (Supplement 1): 2753.

https://doi.org/10.1182/blood-2021-152136

Published: 2021

Journal Articles

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose

Blood (2021) 138 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2021-146940

Published: 2021

Journal Articles

Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

Blood (2021) 138 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2021-144421

Published: 2021

Journal Articles

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Blood (2021) 137 (25): 3495–3506.

https://doi.org/10.1182/blood.2020007303

Published: 2021

Includes: Supplemental data

Journal Articles

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-134538

Published: 2020

Journal Articles

Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study

Thomas Chalopin, Nicolas Vallet, MD, Marlene Ochmann, MD, Mourad Tiab, Pascal Godmer, Carole Barin, Olivier Theisen, MD, Olivier Herault, MD PhD, Emmanuel Gyan, MD PhD, Lotfi Benboubker, MD, Philippe Moreau, MD, Herve Avet-Loiseau, Cyrille Touzeau

Blood (2020) 136 (Supplement 1): 15–17.

https://doi.org/10.1182/blood-2020-139436

Published: 2020

Journal Articles

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Blood (2019) 134 (Supplement_1): 807.

https://doi.org/10.1182/blood-2019-126773

Published: 2019

Journal Articles

Maintenance with Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (IFM 2012-03)

Arthur Bobin, Guillemette Fouquet, Alain Duhamel, PU/PH, Salomon Manier, MD PhD, Lionel Karlin, MD, Brigitte Kolb, MD, Mourad Tiab, MD, Carla Araujo, MD, Nathalie Meuleman, PhD MD, Jean Valère Malfuson, MD, Pascal Bourquard, MD, Pascal Lenain, MD, Arnaud Jaccard, MD PhD, Karim Belhadj, MD, Michel Attal, MD PhD, Philippe Moreau, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD

Blood (2019) 134 (Supplement_1): 3190.

https://doi.org/10.1182/blood-2019-131793

Published: 2019

Journal Articles

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Blood (2018) 132 (24): 2555–2563.

https://doi.org/10.1182/blood-2018-07-863829

Published: 2018

Includes: Supplemental data

Journal Articles

Light Chain Escape in Multiple Myeloma

Thomas Dejoie, MD, Guillemette Fouquet, Cyrille Hulin, Murielle Roussel, Benjamin Hebraud, Lionel Karlin, MD, Brigitte Kolb, MD, Carla Araujo, MD, Nathalie Meuleman, PhD MD, Mourad Tiab, MD, Jean Valère Malfuson, MD, Pascal Bourquard, MD, Pascal Lenain, MD, Arnaud Jaccard, MD PhD, Karim Belhadj, Gérard Lepeu, MD, Marie Lorraine Chretien, MD, Denis Caillot, Jean Fontan, MD, Philippe Rodon, MD, Anna Schmitt, Laurent Voillat, MD, Sophie Cereja, MD, Brigitte Pegourie, MD, Frederique Kuhnowski, MD, Sophie Rigaudeau, MD, Olivier Decaux, MD, Catherine Humbrecht-Kraut, MD, Jamilé Frayfer, MD, Laurent Garderet, Damien Roos-Weil, MD, Jean Claude Eisenmann, MD, Veronique Dorvaux, MD, Eric G. Voog, MD, Claire Mathiot, MD, Jean-Paul Fermand, MD, Thierry Facon, Hervé Avet-Loiseau, MD PhD, Jean Luc Harousseau, MD, Philippe Moreau, Michel Attal, MD PhD, Xavier Leleu, MD PhD

Blood (2018) 132 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2018-99-112396

Published: 2018

NARROW

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose

Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Maintenance with Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (IFM 2012-03)

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Light Chain Escape in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only